T. Gmeiner, J. Grželj, B. Strukelj, Luka Stopar, P. Marko
{"title":"Psoriasis: A Comprehensive Review on the Aetiopathogenesis and Recent Advances in Long-Term Management of Patients with Plaque Psoriasis","authors":"T. Gmeiner, J. Grželj, B. Strukelj, Luka Stopar, P. Marko","doi":"10.4236/pp.2020.1112030","DOIUrl":null,"url":null,"abstract":"Immense changes have been introduced in psoriasis \ntreatment, including successful \nsystemic treatment of inflammation and education of psoriatic patients. \nThe focus of this review is the latest developments in the understanding of the aetiopathogenesis of \npsoriasis, the significance of its comorbidities, treatment possibilities and \nlong-term management using the latest insight provided by pharmacogenetics and \nidentification of biomarkers. The successful control of the disease leads to \nreduction of myocardial infarction and long-term cardiovascular risk but is \nusually achieved after various therapeutic attempts until the best-matched \ntreatment for the individual is identified. There is a high unmet medical need \nfor revealing biomarkers associated with disease prognosis, comorbidities, \nresponse to therapy and adverse effects. More studies have to be performed for \nidentification and validation of biomarkers and implementation of personalized \nmedicine into clinical practice.","PeriodicalId":19875,"journal":{"name":"Pharmacology & Pharmacy","volume":"30 1","pages":"373-401"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/pp.2020.1112030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Immense changes have been introduced in psoriasis
treatment, including successful
systemic treatment of inflammation and education of psoriatic patients.
The focus of this review is the latest developments in the understanding of the aetiopathogenesis of
psoriasis, the significance of its comorbidities, treatment possibilities and
long-term management using the latest insight provided by pharmacogenetics and
identification of biomarkers. The successful control of the disease leads to
reduction of myocardial infarction and long-term cardiovascular risk but is
usually achieved after various therapeutic attempts until the best-matched
treatment for the individual is identified. There is a high unmet medical need
for revealing biomarkers associated with disease prognosis, comorbidities,
response to therapy and adverse effects. More studies have to be performed for
identification and validation of biomarkers and implementation of personalized
medicine into clinical practice.